EP
CRSP icon

Elkhorn Partners’s CRISPR Therapeutics CRSP Stock Holding History

Elkhorn Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.4K Buy
1,900
+240
+14% +$12.7K 0.06% 30
2025
Q4 		$87K Sell
1,660
-540
-25% -$32.3K 0.06% 29
2025
Q3 		$143K Sell
2,200
-1,800
-45% -$103K 0.1% 21
2025
Q2 		$195K Sell
4,000
-200
-5% -$7.74K 0.14% 20
2025
Q1 		$143K Buy
4,200
+400
+11% +$17K 0.09% 21
2024
Q4 		$150K Buy
3,800
+700
+23% +$33.1K 0.1% 22
2024
Q3 		$146K Buy
3,100
+2,100
+210% +$107K 0.09% 23
2024
Q2 		$54K Buy
+1,000
New +$57.8K 0.04% 36
2023
Q4 		– Sell
-250
Closed -$11K – 50
2023
Q3 		$11K Buy
250
+220
+733% +$11.4K 0.01% 46
2023
Q2 		$2K Sell
30
-570
-95% -$32.3K ﹤0.01% 48
2023
Q1 		$27K Sell
600
-750
-56% -$36.4K 0.02% 41
2022
Q4 		$55K Buy
+1,350
New +$71.6K 0.04% 29
2022
Q2 		– Sell
-550
Closed -$35K – 49
2022
Q1 		$35K Buy
550
+200
+57% +$12.6K 0.02% 39
2021
Q4 		$27K Buy
350
+225
+180% +$19.7K 0.02% 36
2021
Q3 		$14K Hold
125
– – 0.01% 40
2021
Q2 		$20K Buy
+125
New +$15.2K 0.01% 37

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Elkhorn Partners's CRSP Position: Q1 2026 in Review

Elkhorn Partners increased its CRISPR Therapeutics (CRSP) stake by 14% in Q1 2026, buying an estimated $12.7K and bringing the position to 1,900 shares worth $90.4K. The position accounts for 0.06% of the portfolio, ranked #30.

Elkhorn Partners first reported a position in CRSP in Q2 2021 and has held it in 16 quarters since. The position peaked at $195K in Q2 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Elkhorn Partners held 1,900 shares of CRISPR Therapeutics worth $90.4K as of Q1 2026.
  • Elkhorn Partners bought 240 CRISPR Therapeutics shares in Q1 2026, an estimated $12.7K.
  • CRISPR Therapeutics made up 0.06% of Elkhorn Partners's portfolio in Q1 2026, its #30 holding.
  • Elkhorn Partners first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Elkhorn Partners's CRISPR Therapeutics position peaked at $195K in Q2 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Elkhorn Partners's 13F filing for Q1 2026, filed 14 May 2026.